The investment seeks to track, before fees and expenses, the performance of the IBD® Breakout Stocks Index (the index). The fund will normally invest at least 80% of its net assets (including investment borrowings) in the equity securities that comprise the index. The index seeks to provide opportunistic investment exposure to those stocks with the potential to break out, or experience a period of sustained price growth beyond the stock's recent resistance level, with consideration for various market conditions. The fund is non-diversified.
|BIO||Bio-Rad Laboratories, Inc||7.05 %|
|VRTX||Vertex Pharmaceuticals Incorporated||6.98 %|
|AMD||Advanced Micro Devices, Inc||6.86 %|
|PYPL||PayPal Holdings, Inc||6.83 %|
|DHR||Danaher Corporation||6.68 %|
|REYN||Reynolds Consumer Products Inc||6.67 %|
|ABT||Abbott Laboratories||5.90 %|
|WST||West Pharmaceutical Services, Inc||5.83 %|
|SPGI||S&P Global Inc||5.83 %|
|POOL||Pool Corporation||5.71 %|
|VOT||Vanguard Mid-Cap Growth Index ..||0.07 %||
|IWP||iShares Russell Mid-Cap Growth..||0.24 %||
|IJK||iShares S&P Mid-Cap 400 Growth..||0.24 %||
|MDYG||SPDR S&P 400 Mid Cap Growth ET..||0.15 %||
|IVOG||Vanguard S&P Mid-Cap 400 Growt..||0.15 %||
|PXMG||Invesco S&P MidCap Momentum ET..||0.39 %||
|KOMP||SPDR S&P Kensho New Economies ..||0.20 %||
|JKH||iShares Morningstar Mid-Cap Gr..||0.30 %||
|XMMO||Invesco S&P MidCap Momentum ET..||0.39 %||
|RFG||Invesco S&P MidCap 400 Pure Gr..||0.35 %||
|Market Performance vs.
Industry/Classification (Mid-Cap Growth)
|Market Performance vs. Exchange|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||7.82%||56%||F||86%||B|
|Risk Adjusted Return||1.30%||27%||F||21%||F|
|Letter Grade||Percentage||Letter Grade||Percentage||Letter Grade||Percentage|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company has under performed its peers on annual average total returns in the past 5 years.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.